Researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), have published a review on BH3 mimetics—a new class of drugs that are reshaping the treatment landscape for acute myeloid ...
Oct 23, 2025
0
14
Researchers from Rutgers Health and other institutions have discovered why a powerful leukemia drug eventually fails in most patients—and found a potential way to overcome that resistance.
Oct 17, 2025
0
98
Personalized drug treatments have outperformed chemotherapy for leukemia patients in a trial led by Leeds researchers. Newly published, long-term results of the UK-wide FLAIR trial could transform treatment for chronic lymphocytic ...
Jun 17, 2025
0
25
A combination of two drugs could improve outcomes and reduce the need for toxic chemotherapy for B-cell acute lymphoblastic leukemia (B-ALL), the most common cancer in childhood and one that can be particularly difficult ...
May 20, 2025
0
23
About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease advance or recur following treatment. Seeking a new treatment strategy that might boost the effectiveness ...
Dec 10, 2024
0
13
Researchers at the Icahn School of Medicine at Mount Sinai have discovered how genetics can affect the success of venetoclax, a treatment for multiple myeloma, a rare type of blood cancer. Their study, "Predictors of Response ...
Nov 29, 2024
0
27
Researchers from Children's Hospital of Philadelphia (CHOP) have discovered the underlying biology that identifies a subset of patients with acute lymphoblastic leukemia who have a higher risk version of the disease and are ...
Nov 25, 2024
0
23
Chromosomal instability plays a crucial role in the progression of cancer: it shapes the properties of tumor cells and drives the development of therapy resistance. Scientists from the German Cancer Research Center (DKFZ), ...
Nov 25, 2024
0
26
Researchers from the Tumor Profiler consortium have combined single-cell multi-omics and functional profiling for 21 AML patients to reveal resistance mechanisms to the Bcl-2 inhibitor venetoclax and identify emerging treatment ...
Nov 11, 2024
0
38
Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells—a type of cancer immunotherapy—that can be switched on to varying degrees of intensity and then switched off on demand with ...
Oct 22, 2024
0
78
